Certara, Inc. Q2 2026 Earnings Call Summary
Certara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.
How this was made
The 30-second read
Why it matters
The call centers on (1) reaffirmed FY revenue guidance (0% to 4%), (2) adjusted EBITDA margin guidance revised to 29% to 31% due to new business composition, (3) a new $50M share repurchase program, and (4) an NVIDIA partnership framed as modernization of software consumption without specific financial timing.
Market read
Traders can update positioning based on the updated margin range, the software mix trajectory (53% of revenue), and the new buyback authorization, while monitoring the unquantified NVIDIA monetization timeline.
What to watch
Stranded costs from the divestiture could keep margins pressured longer than management’s composition-only framing suggests, and the NVIDIA partnership impact is not quantified.
Background
Certara is repositioning from a generalist sales model toward specialist, scientist-led engagement, after divesting its regulatory and medical writing business.
Ticker impact
Certara reaffirmed FY revenue guidance of 0% to 4% and revised adjusted EBITDA margin to 29% to 31% after its regulatory divestiture.
Likely choppy-to-neutral reaction unless investors focus on software mix shift (53% vs 40%) and AI platform monetization timing.
The article provides concrete forward guidance ranges, margin composition change, and a new $50M repurchase program, but lacks quantified impact from the NVIDIA partnership or pipeline conversion.
Market effects
Highlights ongoing enterprise software shift toward higher-margin, cloud-based modeling platforms in regulated life sciences.
International expansion emphasis targets Europe, Asia, and China, potentially affecting regional demand expectations for modeling software.
ICH M15 harmonization is cited as a tailwind for model-informed drug development across US and Europe, supporting broader industry adoption.
Counterpoint
The software mix improvement may be partly mechanical from divestiture accounting, while services lag and pipeline-to-revenue conversion remains the key overhang.
Key entities
- companyCertara, Inc.
Subject of the earnings call summary, providing guidance, margin range, workforce reduction, and capital return details.
- technology_partnerNVIDIA
Partnership enabling NVIDIA agents to interface with Certara software for earlier drug discovery indicators.
- regulatory_standardICH M15
Harmonizes model-informed drug development across the US and Europe, cited as a quarter tailwind.
